Ariad Pharmaceuticals, Inc. (ARIA) Among The Biotech Players To Watch

Top investors holding these stocks

Ariad, Celldex, and Array have caught the attention of top investors who are strongly betting on them. BlackRock Advisors, Baker Bros Advisors LLC, and Barclays are invested in Array Biopharma Inc (NASDAQ:ARRY). BlackRock and Baker Bros. have more than a million shares of the company.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has BlackRock and FMR LLC invested in it. BlackRock has invested in more than 9 million shares, while FMR LLC has over 15 million shares of the company. For Celldex Therapeutics, Inc. (NASDAQ:CLDX), SEC filings indicate that the largest number of its shares are owned by BlackRock (more than 5 million shares), followed by Prudential Financial (about 3 million shares).

Certainly, if large investors are placing their confidence in these companies, it indicates that they are headed in the right direction.

Conclusion

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Array Biopharma Inc (NASDAQ:ARRY), and Celldex Therapeutics, Inc. (NASDAQ:CLDX) are on the track to quick future growth given their unique approach to disease treatment and their smart commercial strategies. The companies can be expected to transition into profit soon, as their drugs get established in the market and they are able to forge strong partnerships for the development of their future drug candidates. Big investors have spotted potential in these companies, and it would be advisable to follow in their footsteps.

The article These 3 Biotech Stocks Look Interesting originally appeared on Fool.com.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.